Drug Trial Radar · NCT05267886
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
346
Planned (sponsor's estimate)
Start
Mar 5, 2022
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Ottawa Heart Institute Research CorporationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
Conditions
- Shock, Cardiogenic
Interventions
DobutamineDrug
Dobutamine administered according to its clinical dose stage for cardiogenic shock
MilrinoneDrug
Milrinone administered according to its clinical dose stage for cardiogenic shock
Normal SalineDrug
Normal saline running at a standardized rate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary composite outcomeTime frame: Through duration of hospitalization, up to 12 weeks following admission
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota · Not yet recruiting
Hamilton Health Sciences
Hamilton, Ontario, Canada · Recruiting
University of Ottawa Heart Institute
Ottawa, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.